Adopting a Tailored Approach to Managing Unmet Needs in OA Management

Previously, osteoarthritis (OA) was thought to be a disease of chronic overload and impaired biomechanics on the joint that lead to the destruction of the joint’s article cartilage, resulting in inflammation. However, evolving theories link OA to complex inflammatory and metabolic factors, and inadequate pain relief with current treatments is a common aspect of OA treatment which is responsible for a plethora of health care visits and dollars. Additionally, there are concerns about the risks of long-term NSAID and opiate use that have led to the need for education on utilizing pain management tools with your patients with OA.

This CME Outfitters Snack focuses on recognizing the complex pathogenesis of OA, applying The Osteoarthritis Research Society International (OARSI) guidelines to non-surgical management, and evaluating emerging data in order to set realistic goals with patients and meet unmet needs in the management of OA.

At the end of this CME/CE activity, participants should be able to:

• Integrate pain management tools for individual pain and function assessment, goal setting, and monitoring.
• Evaluate emerging treatments to address unmet needs of current osteoarthritis therapies.

The following learning objectives pertain only to those requesting CNE or CPE credit:

• Identify pain management tools for individual pain and function assessment, goal setting, and monitoring.
• Evaluate emerging treatments to address unmet needs of current osteoarthritis therapies.

Supported by an educational grant from Pfizer Inc.

Physicians, PAs, nurse practitioners, and pharmacists.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Wilcox reports that he is a stock shareholder (directly purchased) of Pfizer Inc.

• Tony Graham, MD (peer reviewer) has no disclosures to report.
• Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
• Evan Luberger (planning committee) has no disclosures to report.
• Jan Perez (planning committee) has no disclosures to report.
• Sharon Tordoff (planning committee) has no disclosures to report.
• Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-098-H01-P.

Call us at 877.CME.PROS (877.263.7767).